Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Themis MedicareNSE:THEMISMED -2.71%74 Days Payable is 195.31 as of Mar. 2026, which is 39% above its 10-year median of 140.61. GuruFocus rates NSE:THEMISMED with a GF Score™ of 74/100 and a GF Value™ of ₹149.44 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 927 Drug Manufacturers companies, Themis Medicare ranks better than 72.17% on this metric.
The historical rank and industry rank for Themis Medicare's Days Payable or its related term are showing as below:
NSE:THEMISMED'
s Days Payable Range Over the Past 10 Years
Min: 75.24 Med: 140.61 Max: 182.09
Current: 140.04
During the past 13 years, Themis Medicare's highest Days Payable was 182.09. The lowest was 75.24. And the median was 140.61.
NSE:THEMISMED's Days Payable is ranked better than 72.17% of 927
companies
in the Drug Manufacturers industry
Industry Median: 90.38
vs NSE:THEMISMED: 140.04
Themis Medicare's Days Payable
declined
from Mar. 2025 (227.98) to Mar. 2026 (195.31).
It may suggest that Themis Medicareaccelerated paying its suppliers.
Themis Medicare Days Payable Related Terms
Themis Medicare Days Payable Historical Data
* Premium members only.
The historical data trend for Themis Medicare's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:THEMISMED vs ZTS, UTHR: Days Payable Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Themis Medicare's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Themis Medicare Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Themis Medicare's Days Payable distribution charts can be found below:
* The bar in red indicates where Themis Medicare's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Themis Medicare's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Themis Medicare (NSE:THEMISMED) has a Days Payable of 195.31 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Themis Medicare and its competitors. This is 39% above median its historical median of 140.61. Over the past decade, Themis Medicare's Days Payable has ranged from 75.24 to 182.09. According to the industry distribution chart, Themis Medicare ranks #258 out of 927 companies in the Drug Manufacturers industry, placing it in the top 27.8%.
Is Themis Medicare's Days Payable too high?
Themis Medicare's current Days Payable of 195.31 is 39% above median its 10-year median of 140.61. Over the past 10 years, this metric has ranged from a low of 75.24 to a high of 182.09. The Drug Manufacturers industry median Days Payable is 90.38. Themis Medicare's value of 195.31 is 116.1% above this industry median. Based on the distribution chart, Themis Medicare ranks #258 out of 927 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Themis Medicare has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Themis Medicare's Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Themis Medicare ranks #258 out of 927 companies for Days Payable. This puts Themis Medicare in the upper half of its industry. The industry median Days Payable is 90.38. Themis Medicare's value of 195.31 is 116.1% above this benchmark. Historically, Themis Medicare's own Days Payable has ranged from 75.24 to 182.09 over the past decade. While the company's 10-year median is 140.61 vs. the industry median of 90.38, Themis Medicare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.38, based on 927 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Themis Medicare's current Days Payable of 195.31 is 116.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Themis Medicare and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Themis Medicare's current Days Payable is 195.31, which is 39% above median its own 10-year median of 140.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Themis Medicare stock overvalued right now?
Based on GuruFocus' analysis, Themis Medicare (NSE:THEMISMED) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹149.44, compared to a current price of ₹112.42 — trading 24.8% below its estimated fair value. The current Days Payable is 195.31, which is 39% above median its 10-year median of 140.61 and 116.1% above the Drug Manufacturers industry median of 90.38. Themis Medicare's overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Themis Medicare (NSE:THEMISMED), the current Days Payable is 195.31 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Themis Medicare (NSE:THEMISMED) Overvalued in 2026?
Based on GuruFocus' analysis, Themis Medicare stock appears to be undervalued.
The current stock price of ₹112.42 is trading 24.8% below its estimated GF Value™ of ₹149.44.
GuruFocus considers Themis Medicare to be Modestly Undervalued.
Key valuation signals for NSE:THEMISMED:
Days Payable: 195.31 (39% above median its 10-year median of 140.61)
GF Value™: ₹149.44 vs. price of ₹112.42 (24.8% below fair value)
Industry Position: 116.1% above the Drug Manufacturers median (#258 of 927)
No single metric tells the full story. See the NSE:THEMISMED stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Themis Medicare Ltd is an Indian based company engaged in the manufacturing and marketing of pharmaceutical products. The Company operates only in one business segment which is Pharmaceuticals. Geographically, it derives a majority of revenue from India and also has a presence in the international market. Its product categories include Anti Malarial, CCD products, Nutritional Gummies, and Candy and Other Products such as OD-LM, Dexem, Medzol and Tazowin.
74GF Score
Get the complete analysis for NSE:THEMISMED
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:THEMISMED has been successfully added to your 
